Advances with vaccination against Neisseria meningitidis

Raymond Borrow*

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    20 Citations (Scopus)


    In the last decade, meningococcal serogroup C conjugate vaccination programs have been demonstrated to be hugely successful with a truly impressive public health impact. In sub-Saharan Africa, with the implementation of an affordable serogroup A conjugate vaccine, it is hoped that a similar public health impact will be demonstrated. Challenges still remain in the quest to develop and implement broadly protective vaccines against serogroup B disease. New, broad coverage vaccines against serogroup B are for the first time becoming available although little is known about their antibody persistence, effectiveness or effect on nasopharyngeal carriage. Enhanced surveillance following any potential vaccine introduction against serogroup B needs to be thoroughly implemented. The future now holds a distinct possibility, globally, for substantially decreasing meningococcal disease, regardless of infecting serogroup.

    Original languageEnglish
    Pages (from-to)1478-1491
    Number of pages14
    JournalTropical Medicine and International Health
    Issue number12
    Publication statusPublished - Dec 2012

    Bibliographical note

    Copyright 2014 Elsevier B.V., All rights reserved.


    • Conjugate
    • Meningococcus
    • Polysaccharide
    • Vaccine


    Dive into the research topics of 'Advances with vaccination against Neisseria meningitidis'. Together they form a unique fingerprint.

    Cite this